BACKGROUND. Chickenpox, the primary infection caused by the varicella-zoster virus, affects more than 3 million children a year in the United States. Although usually self-limited, chickenpox can cause prolonged discomfort and is associated with infrequent but serious complications. METHODS. To evaluate the effectiveness of acyclovir for the treatment of chickenpox, we conducted a multicenter, double-blind, placebo-controlled study involving 815 healthy children 2 to 12 years old who contracted chickenpox. Treatment with acyclovir was begun within the first 24 hours of rash and was administered by the oral route in a dose of 20 mg per kilogram of body weight four times daily for five days. RESULTS. The children treated with acyclovir had fewer varicella lesions than those given placebo (mean number, 294 vs 347; P less than 0.001), and a smaller proportion of them had more than 500 lesions (21 percent, as compared with 38 percent with placebo; P less than 0.001). In over 95 percent of the recipients of acyclovir no new lesions formed after day 3, whereas new lesions were forming in 20 percent of the placebo recipients on day 6 or later. The recipients of acyclovir also had accelerated progression to the crusted and healed stages, less itching, and fewer residual lesions after 28 days. In the children treated with acyclovir the duration of fever and constitutional symptoms was limited to three to four days, whereas in 20 percent of the children given placebo illness lasted more than four days. There was no significant difference between groups in the distribution of 11 disease complications (10 bacterial skin infections and 1 case of transient cerebellar ataxia). Acyclovir was well tolerated, and there was no significant difference between groups in the titers of antibodies against varicella-zoster virus. CONCLUSIONS. Acyclovir is a safe treatment that reduces the duration and severity of chickenpox in normal children when therapy is initiated during the first 24 hours of rash. Whether treatment with acyclovir can reduce the rare, serious complications of chickenpox remains uncertain.
Source Information
Department of Pediatrics, St. Louis University.
This article has been cited by other articles:
(2009). Picture of the Month--Diagnosis. Arch Pediatr Adolesc Med
163: 482-482
[Full Text]
Gershon, A. A.
(2008). Varicella-Zoster Virus Infections. Pediatr. Rev.
29: 5-11
[Full Text]
Harris, D, Redhead, J
(2005). Should acyclovir be prescribed for immunocompetent children presenting with chickenpox?. Arch. Dis. Child.
90: 648-650
[Full Text]
Mohsen, A H, Peck, R J, Mason, Z, Mattock, L, McKendrick, M W
(2001). Lung function tests and risk factors for pneumonia in adults with chickenpox. Thorax
56: 796-799
[Abstract][Full Text]
Kurokawa, M., Hozumi, T., Tsurita, M., Kadota, S., Namba, T., Shiraki, K.
(2001). Biological Characterization of Eugeniin as an Anti-Herpes Simplex Virus Type 1 Compound in Vitro and in Vivo. J. Pharmacol. Exp. Ther.
297: 372-379
[Abstract][Full Text]
Kimura, H., Kido, S., Ozaki, T., Tanaka, N., Ito, Y., Williams, R. K., Morishima, T.
(2000). Comparison of Quantitations of Viral Load in Varicella and Zoster. J. Clin. Microbiol.
38: 2447-2449
[Abstract][Full Text]
Cohen, J. I., Brunell, P. A., Straus, S. E., Krause, P. R.
(1999). Recent Advances in Varicella-Zoster Virus Infection. ANN INTERN MED
130: 922-932
[Abstract][Full Text]
Balfour, H. H.
(1999). Antiviral Drugs. NEJM
340: 1255-1268
[Full Text]
Kurokawa, M., Basnet, P., Ohsugi, M., Hozumi, T., Kadota, S., Namba, T., Kawana, T., Shiraki, K.
(1999). Anti-Herpes Simplex Virus Activity of Moronic Acid Purified from Rhus javanica In Vitro and In Vivo. J. Pharmacol. Exp. Ther.
289: 72-78
[Abstract][Full Text]
Kurokawa, M., Hozumi, T., Basnet, P., Nakano, M., Kadota, S., Namba, T., Kawana, T., Shiraki, K.
(1998). Purification and Characterization of Eugeniin as an Anti-herpesvirus Compound from Geum japonicum and Syzygium aromaticum. J. Pharmacol. Exp. Ther.
284: 728-735
[Abstract][Full Text]
Kuppermann, N., Bank, D. E., Walton, E. A., Senac, M. O. Jr, McCaslin, I.
(1997). Risks for Bacteremia and Urinary Tract Infections in Young Febrile Children With Bronchiolitis. Arch Pediatr Adolesc Med
151: 1207-1214
[Abstract]
Balfour, H.
(1995). Author's reply. BMJ
310: 1268c-1269
[Full Text]
McKendrick, M W
(1995). Controversies in Management: Acyclovir for childhood chickenpox. BMJ
310: 108-109
[Full Text]
Balfour Jr, H. H
(1995). No reason not to treat. BMJ
310: 109-110
[Full Text]
Anderson, D. R., Schwartz, J., Hunter, N. J., Cottrill, C., Bisaccia, E., Klainer, A. S.
(1994). Varicella Hepatitis: A Fatal Case in a Previously Healthy, Immunocompetent Adult: Report of a Case, Autopsy, and Review of the Literature. Arch Intern Med
154: 2101-2106
[Abstract]
Duvic, M., Grossman, D.
(1994). More on Acyclovir for Chickenpox. NEJM
331: 59-59
[Full Text]
Lieu, T. A., Cochi, S. L., Black, S. B., Halloran, M. E., Shinefield, H. R., Holmes, S. J., Wharton, M., Washington, A. E.
(1994). Cost-effectiveness of a Routine Varicella Vaccination Program for US Children. JAMA
271: 375-381
[Abstract]
Goldberg, L. H., Kaufman, R., Kurtz, T. O., Conant, M. A., Eron, L. J., Batenhorst, R. L., Boone, G. S., the Acyclovir Study Group,
(1993). Long-term Suppression of Recurrent Genital Herpes With Acyclovir: A 5-Year Benchmark. Arch Dermatol
129: 582-587
[Abstract]
Wallace, M. R., Bowler, W. A., Murray, N. B., Brodine, S. K., Oldfield, E. C. III
(1992). Treatment of Adult Varicella with Oral Acyclovir: A Randomized, Placebo-controlled Trial. ANN INTERN MED
117: 358-363
[Abstract]
(1991). ACYCLOVIR SPEEDS RESOLUTION OF CHICKENPOX. JWatch General
1991: 7-7
[Full Text]
Previous
